The efficacy of daclizumab for intestinal transplantation: preliminary report.
Abu-Elmagd
K
K
Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213, USA. kae@med.pitt.edu
Fung
J
J
McGhee
W
W
Martin
D
D
Mazariegos
G
G
Schaefer
N
N
Demetris
J
J
Starzl
T E
TE
Reyes
J
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002648:Child; D000077561:Daclizumab; D005260:Female; D006084:Graft Rejection / Q000473:pathology; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007422:Intestines / Q000473:pathology / Q000637:transplantation*; D008297:Male; D014184:Transplantation, Homologous / Q000276:immunology* / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab